North America Digital Diabetes Management Market

North America Diabetes Care Devices Market Analysis

The North America Diabetes Care Devices Market size is estimated at USD 29.23 billion in 2025, and is expected to reach USD 39.50 billion by 2030, at a CAGR of 6.21% during the forecast period (2025-2030).

The PAHO Panorama of Diabetes report highlights the alarming increase in diabetes cases in the Americas. The projected number of individuals affected by diabetes is expected to rise from 62 million in 2022 to 109 million by 2040 if current patterns persist. This emphasizes the urgent need for increased awareness, prevention, and management strategies to address this growing public health challenge. Further, the report emphasizes the importance of early detection and diagnosis, as many individuals may be living with diabetes without even realizing it. This lack of awareness can delay necessary treatment and increase the risk of complications. Therefore, efforts to improve screening and testing for diabetes are crucial to identify and support those who are affected.

The North American region has witnessed an astounding increase in the prevalence of diabetes, in recent years. In developed countries, such as the United States and Canada, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people.

Patients with Type 2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy. This is driving the demand for diabetes care devices in North America, thereby driving the market in focus during the forecast period.

North America Diabetes Care Devices Market Trends

Monitoring Devices is Having the Highest Market Share in Current Year

Monitoring devices are garnering widespread adoption due to the availability of reimbursement options for glucose meters. Glucose meter devices must be replaced within six to eight months and are very expensive. As a result, most people prefer selecting health insurance plans that cover almost 80% of the total expenditure on healthcare devices.

Such schemes cover the cost of diabetes testing supplies, blood glucose test strips, and blood glucose meters. For example, Medicare, the federal health insurance program in the United States, covers approximately 80% of the cost of BGM devices for diabetic people.

The usage of CGM devices is on the rise in North America because of their advancement in technology and their ability to empower people with diabetes to make more informed decisions about their health. This is driving the demand for diabetes care devices in North America, thereby driving the market in focus during the forecast period.

The United States is Expected to Dominate the North America Diabetes Care Devices Market.

The United States is expected to grow tremendously during the forecast period, owing to factors such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.

According to the American Diabetes Association, 1.4 million Americans are thought to receive a diabetes diagnosis each year. In Canada and other North American nations, diabetes is one of the main killers. The disease's rising incidence, prevalence, and progressive nature have motivated the development of novel medications to give diabetic patients more treatment options. Non-insulin medications, which serve as first-line therapies for people with type-2 diabetes, currently account for more than half of sales in the anti-diabetic market.

Innovations in insulin pump devices in the United States are driving the market. Medtronic received FDA clearance for its new extended-wear infusion set, designed to last more than twice as long as existing infusion sets that connect traditional tubed pumps to the body for insulin delivery.

That means it can be worn on the body for up to 7 days, compared to existing sets that must be changed every 2 or 3 days. In the United States, there are innovations from start-up companies with approximately USD 2.9 billion in funding in the diabetes industry, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, Orgenesis, etc. Thus, owing to the above factors, it is expected to drive market growth over the forecast period.

North America Diabetes Care Devices Industry Overview

A select few big players control the market. Abbott's new FreeStyle Libre Flash glucose monitoring system was approved, which is the first continuous blood sugar monitor for people with diabetes that does not need backup finger prick tests. Innovations in test strips are increasing and are under development. For example, the new test strip includes features such as underfill detection and provides the user with the ability to reapply blood when the test strip is underfilled ("second chance" sampling). Dexcom acquired TypeZero Technologies, paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead in the race to create an artificial pancreas system rather than simply offering a continuous glucose monitoring device.

North America Diabetes Care Devices Market Leaders

North America Diabetes Care Devices Market News

• April 2023: Abbott has announced the clearance of its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system by the U.S. Food and Drug Administration (FDA). This system includes a reader that has been approved as a standalone device. Notably, the glucose sensor used in this system is the smallest, thinnest, and most discreet in the world. Abbott is now focused on expediting the process of getting the FreeStyle Libre 3 system included in Medicare's list of covered systems.
• March 2022: Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.